Key Takeaways:
- Wegovy (semaglutide 2.4 mg) is injected once weekly, whereas Saxenda (liraglutide 3.0 mg) requires a once-daily subcutaneous injection.
- In head-to-head STEP-8 clinical trial data (68 weeks), weekly semaglutide achieved ~15.8% mean body-weight loss compared with ~6.4% on daily liraglutide alongside lifestyle counseling.
- Both medications qualify adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition such as hypertension, dyslipidemia, prediabetes, or obstructive sleep apnea.
- Because both act on GLP-1 receptors, they are never taken together—clinicians select one based on tolerability, medical history, and availability.
Head-to-Head Clinical Comparison: Semaglutide vs. Liraglutide
| Feature | Wegovy (Semaglutide) | Saxenda (Liraglutide) |
|---|---|---|
| Active Ingredient | Semaglutide (long-acting GLP-1 agonist) | Liraglutide (short-acting GLP-1 agonist) |
| Injection Frequency | Once weekly (7-day half-life) | Once daily (~13-hour half-life) |
| Titration Schedule | 16–20 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/wk) | 5 weeks (0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg/day) |
| STEP-8 Trial Mean Weight Loss | ~15.8% at 68 weeks | ~6.4% at 68 weeks |
Why Some Patients Still Use Daily Liraglutide
While once-weekly semaglutide (and dual GIP/GLP-1 tirzepatide) now lead clinical weight-loss efficacy and convenience, daily liraglutide clears from the body within 2 to 3 days—offering faster dose-step flexibility for patients who prefer shorter-acting titration under medical guidance.
Leave a Reply